{"analyses":[{"ciLowerLimit":"0.41","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.69","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.53","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"133"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"229"}],"units":"Participants"}],"description":"Patients who develop progression (defined in primary outcome measure), died or develop a new primary malignancy (cancer) will summarized in this outcome.","groups":[{"description":"Beginning between day 100-110, patients receive oral lenalidomide once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.","id":"OG000","title":"Lenalidomide Maintenance"},{"description":"Beginning between day 100-110, patients receive oral placebo once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.\n\n(closed as of 12/17/09)","id":"OG001","title":"Placebo Maintenance"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 10 years)","title":"Number of Participants With Progression, Death or Diagnosis of Second Primary Malignancy","type":"POST_HOC","unitOfMeasure":"participants"}